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The in vivo phosphorylation stoichiometries of 4 serines on the glycogen-binding (G)-subunit of protein phosphatase 1(PPl) have been determined. 
In fed rabbits injected with propranolol stoichiometries (mol/mol) were: site 1 (0.67+0.09), site 2 (0.20+0.07), site 3a (0.23 kO.01) and site 3b 
(0). After injection with adrenalin they became: site 1 (0.90&0.02), site 2 (0.72&0.01), site 3a (0.23kO.02) and site 3b (0). These results, together 
with other data, establish that site 2 phosphorylation by cyclic AMP-dependent protein kinase triggers dissociation of PPI from the G-subunit 
in vivo. They also demonstrate that a residue phosphorylated in vitro by glycogen synthase kinase 3 (site 3a) is phosphorylated in vivo. 
Protein phosphatase; Glycogen metabolism; Adrenaline; cyclic AMP; Protein kinase 
1. INTRODUCTION 2. MATERIALS AND METHODS 
The glycogen-bound form of protein phosphatase 1 
(PPlo) is a heterodimer comprising the 37 kDa catalyt- 
ic (C) subunit and a 161 kDa glycogen-binding (G)-sub- 
unit, whose interaction is regulated by the cyclic AMP- 
dependent protein kinase (PKA) catalysed phos- 
phorylation of the G-component [l-3]. Initial investiga- 
tions suggested the presence of a single phosphoserine 
[4], now termed site 1, that was shown to be phos- 
phorylated in vivo [5], but subsequent in vitro studies 
revealed 3 further phosphoserines. One, termed site 2 
(19 residues C-terminal to site l), was also phos- 
phorylated by PKA, and missed in earlier work for 
reasons discussed in [3,6]. The other serines, termed 
sites 3a and 3b, are located 4 and 8 residues N-terminal 
to site 1 and phosphorylated by glycogen synthase 
kinase 3 (GSK3), provided that site 1 is phosphorylated 
by PKA [7,8]. The sequence of this 48 residue regulato- 
ry domain is: AIFKPGFSPQPSRRGSESSEEVYVHT 
ASSGGRRVSFADNFGFNLVSVK [3,7], where the 
lst, 2nd, 3rd and 8th serines correspond to sites 3a, 3b, 
1 and 2, respectively. Here, we extend analysis of the in 
vivo phosphorylation state of the G-subunit to encom- 
pass all 4 potential phosphorylation sites using fed ani- 
mals injected with either adrenaline or the antagonist 
propranolol. 
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2.1. Materials 
The sources of all reagents and proteins used in this study are given 
in [5,7]. 
2.2. Generation of tryptic phosphopeptides from protein 
phosphatase lo after injection offed rabbits with propranoloi or 
adrenaline 
Hormone injection, followed by isolation of PPlo from skeletal 
muscle extracts in the presence of phosphatase inhibitors was carried 
out as in [5], with slight modifications to the purification procedure 
[2]. PPlo (2-4 mg, purity Xl-7OW) was mixed with 0.02 mg of 32P- 
labelled PPlo (=300000 cpm) that had been phosphorylated to 
= 3 mol/mol in vitro by the combined action of PKA and GSK3 [S]. 
This trace of ‘marker’ protein enabled the purification and recovery 
of each peptide to be followed. PPlo (0.5 ml) was then incubated 
with trypsin (0.05 mg) for 10 min at 37”C, and digestion terminated 
by addition of 0.05 ml of 100% (w/v) trichloroacetic acid. After cen- 
trifugation for 2 min at 13 000 x g the supernatant, containing = 70% 
of the “P-radioactivity and the tryptic peptides corresponding to sites 
1, 3a and 3b, was removed. The pellet, containing 30% of the 32P- 
radioactivity and the trichloroacetic acid-insoluble tryptic peptide 
containing site 2, was resuspended in 0.1 ml of 100% (v/v) trifluoro- 
acetic acid, placed in a sonicating water bath for 10 min and, after ad- 
dition of 0.1 ml of water, neutralised with solid ammonium bicar- 
bonate. Following centrifugation for 2 min at 13 000 x g, the super- 
natant was removed, the pellet resuspended once more in 0.1 ml of 
trifluoroacetic acid, and the procedure repeated. The combined 
supernatants containing = 70% of the site 2 tryptic phosphopeptide 
were added to the supernatant containing the tryptic peptides corre- 
sponding to sites 1, 3a and 3b and analysed. 
2.3. Other analytical procedures 
Protein concentrations were determined by calorimetric assay [9]. 
Chromatography of peptides was carried out using a 250 x 4 mm 
Vydac 218TP54 reverse-phase C1.g column (Separations Group, 
Hesperia, CA, USA) equilibrated in either 0.1% (v/v) trifluoroacetic 
acid, pH 1.9, or 10 mM ammonium acetate, pH 6.5. The chromato- 
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Fig.1. Gel filtration of tryptic ~~ospho~ptides on Sepbadex G50 
Superfine. Pbosphopeptid~ (1 .O ml} released by brief tryptic diges- 
tion of native PPlo (section 2.2) were applied to column (110 x 1.3 
cm) equilibrated in 0.1 M NH&CO~. The flow rate was 13 ml/h and 
fractions of 1 ml were collected. The graph shows 32P-radioa~t~vity 
derived from the trace of ‘marker’ peptide that was used to locate the 
positions of the tryptic peptides containing sites 1 + 3a + 3b (peak 
A), site I (peak B), site 2 and sites 3a/3b (peak C). T’he horizontal bars 
indicate the fractions pooled and the position of 32P-ATP (traces of 
which contaminated the ‘marker’) is also shown. 
grams were developed with linear waterlacetouitrile gradients with an 
increase in acetonitrile concentration of 0.33% per min and analysed 
on-line for 214 run absorbing material and “P-radioactivity. The 
ffow rates were 1 ml/min and fractions of 0.5 ml were collected. 
Amino acid analysis was carried out with a Waters PICOTAG system 
Tabfe I 
[lo], protein silencing using an Applied Biosystems 470A gas phase 
sequencer equipped with an on-line reverse-phase chromatography 
system for identification of phenylth~ohydantoin (Pth) amino acids, 
and fast atom bomb~dment mass spectrometry (BACKS) in the 
positive ion mode using a VG Analytical 7OSE machine [I 1). 
3. RESULTS 
3. I. Isolation and analysis of tryptic ~b~sp~a~ptides 
The mixture of tryptic peptides containing site 1, site 
2, and sites (3a + 3b) were applied to Sephadex GSO 
(Superfine grade, Pharmacia), which resolved the 32P- 
radioactivity associated with the ‘marker’ peptides into 
3 major peaks, termed A, B and C (fig.1). Peak A was 
~tablished in separate studies (not shown) to comprise 
residues 1-32 of the regulatory domain (section 1) and 
contained sites 1, 3a and 3b. It resulted from the failure 
of trypsin to cleave the Arg-Arg bond in the sequence 
Ser(site 3b)-Arg-~g-Gly-S~r(site l), when both site 3b 
and site 1 were phosphorylated. Peak B (fig. 1) contain- 
ed 90~0 of the tryptic peptide containing site 1 (residues 
14/15-32, section I), while peak C contained the site 2 
tryptic peptide (residues 33/34-48), the tryptic peptide 
contai~ng sites 3a and 3b (residues I-13) and traces of 
the site 1 tryptic peptide. Peaks A, B and C were pooled 
(fig-l), the volume reduced to ~0.5 ml in a vacuum 
concentrator (avoiding compete drying which leads to 
the loss of the site 2 peptide [3,6]), made 1% (by vol.) 
in 0.1% trifluoroacetic acid and chromatographed on
the Cl8 column equilibrated at pH 1.9. 
The 32P-radioactivity in peak A derived from the 
‘marker’ peptide luted from the Cl8 column as a single 
peak at 23.3% acetonitrile, but no 214 nm absorbing 
peak eluted at this position. Amino acid analysis of the 
same region, using preparatians i olated from animals 
injected with either propranolol or adren~ine~ confi~- 
ed the lack of material corresponding to this peptide. 
In vivo phosphorylation stoichiometries of the G-subunit after injection of pro- 
pranolol or adrenaline 
Preparation Injection site 1 site 2 site 3a site 3b 
I propranolol 0.76 f 0.01 0.27 f 0.03 0.23 -f 0.01 0 
2 propra~olol 0.58 f 0.03 0.13 + 0.01 0,23 f 0.01 0 
Ave. of 1 
and 2 propranolol 0.67 Z+Z 0.09 0.20 -f 0.07 0.23 + 0.01 0 
3 adrenaline 0.88 I 0.01 0.72 ZJZ 0.01 0.21 f 0.02 0 
4 adrenaline 0.91 ,e_ 0.03 0.71 i 0.02 0.24 i 0.03 0 
Ave. of 3 
and 3 adrenaline 0.90 it 0.02 0.72 i 0.01 0.23 f 0.02 0 
Phosphorylation stoichiometries were calculated as a ratio of the amount of 
pbosphopeptide to (dephospho~ptide + phosphopeptide). This was determined 
firstly by qu~ti~tive amino acid analysis of the separated phospho- and 
depbospho-peptid~, and secondly by comparison of the areas under the 214 nm 
absorbance peaks corresponding to the phospho- and dephosphopeptides ( ee 
figs.2 and 3). Values obtained by each procedure were then averaged to yield the 
values shown 
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The 32P-radioactivity in peak B eluted from the Crs 
column at 17.3% acetonitrile, and FABMS analysis 
(not shown) demonstrated that it contained both the 
site 1 phosphopeptide RGS(P)ESSEEVYVHTASSGGR 
([M + H]+ = 2075) and a dephosphorylated derivative 
GSESSEEVYVHTASSGGR ([M + H]+ = 1839), which 
were resolved by a further chromatography at pH 6.5 as 
reported previously [5]. Phosphorylation stoichio- 
metries presented in table 1 were similar to the values 
reported previously [5]. 
Chromatography of peak C on the Cl8 column, 
resolved the tryptic peptides containing sites (3a + 3b) 
and site 2. The “P-1abelled ‘marker’ corresponding to 
the sites (3a + 3b) tryptic peptide (residues 1-13, see 
section 1) eluted at 21% acetonitrile and FABMS 
analysis of this region revealed molecular ions 
([M + H] ‘) of 1512 and 1432 corresponding to 
monophosphorylated and dephosphorylated deriva- 
tives. No diphosphorylated derivtive ([M + H+] = 
1592) was detectable in earlier eluting fractions by 
either FABMS or amino acid analysis. The region con- 
propranolol 
P 
& 
0 
adrenalin 
ii 
L 
P 
+!JL, 
60 64 68 
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Fig.2. Reverse-phase chromatography at pH 6.5 of the tryptic pep- 
tides containing sites 3a and 3b. The peptide from propranolol (upper 
trace) or adrenaline (lower trace) treated animals were resolved into 
phospho- (P) and dephospho- (D) forms (detected by monitoring ab- 
sorbance at 214 nm) which were eluted at 20.36 and 22.2070 
acetonitrile, respectively. Further details are given in sections 2.3 and 
Fig.3. Reverse-phase chromatography at pH 6.5 of the tryptic pep- 
tides containing site 2. The peptides from propranolol (upper trace) or 
adrenaline (lower trace) treated animals was resolved into 3 com- 
ponents. The monophosphorylated erivative (P) and two depho- 
sphorylated peptides Dl and D2 (detected by monitoring absorbance 
at 214 nm), were eluted at 26.7%, 29.3% and 30.2% acetonitrile, 
respectively. Peptide D2 contains an additional arginine residue at its 
N-terminus compared to Dl. Further details are given in sections 2.3 
3.1. The unmarked peaks are unrelated peptides. and 3.1. The unmarked peaks are unrelated peptides. 
taining the phosphopeptide and dephosphopeptide 
(21.0-22.6010 acetonitrile) was pooled, dried and re- 
chromatographed at pH 6.5. This procedure resolved 
and purified the two derivatives (fig.2) which were iden- 
tified by FABMS. Phosphorylation stoichiometries are 
presented in table 1. 
The 32P-labelled ‘marker’ corresponding to the site 2 
tryptic phosphopeptide eluted at 30.7010 acetonitrile. 
FABMS analysis revealed than the phosphopeptide 
RVS(P)FADNFGFNLVSVK ([M + H]+ = 1880) 
coeluted with the dephosphopeptide VSFADNFGFN- 
LVSVK ([M + H] + = 1644), an analogous result to 
that obtained with the site 1 tryptic peptide [5]. A se- 
cond form of the dephosphorylated peptide was also 
present ([M + H] + = 1800), which contained an addi- 
tional arginine at its N-terminus, and eluted later at 
32.0% acetonitrile. The entire region from 30.7-32.0% 
acetonitrile was pooled, reduced to = 0.2 ml and chro- 
matographed at pH 6.5. This procedure resolved and 
purified the phosphopeptide and both dephosphopep- 
tides (fig.3), which were identified by FABMS. Phos- 
phorylation stoichiometries are presented in table 1. 
The tryptic phosphopeptide containing site 1 is 
phosphorylated in vivo [5] on the same serine that is 
phosphorylated in vitro by PKA [4]. In order to deter- 
mine which serines in the site 2 and site (3a + 3b) tryp- 
tic peptides were phosphorylated, phosphoserine 
adrenalin 
I 
pmprandol 
I 1 1 I I I I I I 
80 84 88 92 
time (min) 
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Time 1 minutes 1 
Fig.4. Sequence analysis of the monophosphorylated site 2 tryptic 
peptide after incubation with NaOH and ethanethiol (section 2.3). 
The peptide (residues 33-48, section 1) isolated from propranolol- 
treated animals was incubated for 1 h with ethanethiol, dried and the 
residue washed twice with water, redissolved in 0.1% (v/v) tri- 
fluoroacetic acid containing 50% acetonitrile and analysed on the gas 
phase sequencer. The figure shows reverse-phase chromatograms of 
Pth derivatives corresponding to the first 4 cycles. The amount ap- 
plied to the sequencer was 275 pmol. The absorbance scale is o-0.03. 
The phenylthiohydantoin derivative of serine was detected as its 
dithiothreitol adduct (DTT-S). Other abbreviations: R, Pth-arginine; 
V, Pth-valine; S-EtC, Pth-S-ethylcysteine; F, Pth-phenylalanine; a,b 
and c are dimethylphenylthiourea, diphenylthiourea nd diphenyl- 
urea, respectively. 
10 20 
Time (’ minutes I 
Fig.5. Sequence analysis of the monophosphorylated tryptic peptide 
containing sites 3a and 3b after incubation with NaOH and 
ethanethiol (section 2.3). The peptide (residues l-13, section 1) 
isolated from propranolol-treated animals was incubated for 6 h with 
ethanethiol. The figure shows reverse-phase chromatograms of Pth 
derivatives corresponding to residues 7-12. The amount applied to the 
sequencer was 600 pmol and the absorbance scale is O-0.005. Ab- 
breviations: G, Pth-glycine; P, Pth-proline; Q, Pth-glutamine; S,Pth- 
serine. The glycine present at residue 7 is carryover from the previous 
cycle. Further details and other abbreviations are given in the legend 
to fig.4. 
residues in the monophosphorylated derivatives 
(figs.2,3) were converted to S-ethylcysteine [12,13] and 
sequenced. After the third cycle of Edman degradation 
the site 2 peptide from propranolol (fig.4) and 
adrenaline (not shown) treated animals revealed the 
presence of Pth-S-ethylcysteine, while only traces of 
Pth-Ser (dithiothreitol adduct), no higher than at the 
previous cycle, were present (fig.4). At the 14th cycle 
Pth-Ser and its dithiothreitol adduct were present but 
no Pth-S-ethylcysteine was found (not shown). Similar 
analysis of the tryptic peptide containing sites 3a and 
3b, established that only site 3a was phosphorylated 
(fig.5). The phosphoserine residue at site 3a was very 
resistant o P-elimination of the phosphate moiety, and 
a 6 h (instead of the usual 1 h) reaction was required for 
conversion to S-ethylcysteine explaining why small 
amounts of Pth-Ser (dithiothreitol adduct) were observ- 
ed at this cycle. The resistance of phosphoseryl-proline 
bonds to alkaline hydrolysis has been noted previously 
H41. 
4. DISCUSSION 
A procedure has been devised that allows the in vivo 
phosphorylation states of 4 potential phosphoserine 
residues on the G-subunit to be quantitated. Phospho- 
peptides and their dephosphorylated counterparts are 
copurified through gel filtration at pH 8 and chroma- 
tography on a Cl8 column at pH 1.9, and finally resolv- 
ed by chromatography on the Cl8 column at pH 6.5. 
The phosphorylation stoichiometries (table 1) assume 
that recoveries of phosphopeptides are identical to 
dephosphopeptides through all steps of purification 
and that the presence of fluoride and inorganic 
pyrophosphate prevents any dephosphorylation of the 
G-subunit during its isolation [5]. The latter assumption 
is clearly valid, at least for site 1 and site 2, since near 
stoichiometric phosphorylation of these serine residues 
is observed in response to adrenaline (table 1). 
Recent in vitro studies have established that phos- 
phorylation of the G-subunit by PKA is accompanied 
by dissociation of the C-subunit, the extent of dis- 
sociation correlating with the state of phosphorylation 
of site 2, but not site 1 [3]. Intravenous injection of 
adrenaline promotes dissociation of the G and C sub- 
units in vivo, increasing (from 35 to 70%) the propor- 
tion of PPl activity remaining in the cytosol after 
sedimentation of glycogen particles [5,15]. The propor- 
tion of PPl in cytosol correlates well with the in vivo 
phosphorylation state of site 2, but not site 1 (table 1). 
A perfect correlation would not be expected since 100% 
of the PPlc in muscle extracts does not sediment with 
glycogen [5], and small amounts of other active forms 
of PPl, distinct from PPlo, might also be present in the 
extracts. The free C subunit has = 5-fold lower activity 
than PPlo towards glycogen phosphorylase and 
glycogen synthase when assayed at physiological ionic 
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strength and under conditions where both PPlo and 
these two substrates are bound to glycogen [16]. Thus 
subunit dissociation is a mechanism for preventing the 
dephosphorylation of glycogen-bound substrates in 
response to adrenaline [16]. 
Although phosphorylation of site 2 triggers subunit 
dissociation, a role for site 1 phosphorylation in this 
process is not yet excluded [6]. Site 1 has a further func- 
tion in permitting phosphorylation of sites 3a and 3b by 
GSK3 in vitro [9, lo]. The present study has established 
that one of the serines phosphorylated by GSK3 (site 3a) 
is also phosphorylated in vivo, but the stoichiometry 
seems to be low and does not alter in response to 
adrenaline, despite a high level of site 1 phosphoryla- 
tion [5], table 1). The high phosphorylation of site 1 in 
the absence of adrenaline may be explained by its 
resistance to dephosphorylation [3] and/or phospho- 
rylation by a protein kinase distinct from PKA. We are 
now studying the effects of site 1, 3a and 3b pho- 
sphorylation in vitro on activity and how insulin alters 
their phosphorylation in vivo. 
Acknowledgements: We would like to thank Drs Michael Hubbard, 
Carl Smythe and Carol MacKintosh for their constructive advice 
throughout this work. This work was supported by Grants from the 
Medical Research Council London and The Royal Society. P.D. is the 
recipient of a postgraduate studentship from the Wellcome Trust. 
REFERENCES 
HI 
121 
[31 
141 
PI 
161 
[71 
PI 
[91 
DOI 
Ull 
WI 
1131 
[I41 
1151 
Stralfors, P., Hiraga, A. and Cohen, P. (1985) Eur. J. Biochem. 
149, 295-303. 
Cohen, P., MacKintosh, C. and Hubbard, M.J. (1989) in: Adv. 
Prot. Phosphatases, Vol. 5, (eds) W. Merlevede and J. Di Salvo, 
pp. 1-17, Leuven University Press, Belgium. 
Hubbard, M.J. and Cohen, P. (1989a) Eur. J. Biochem. in 
press. 
Caudwell, F.B., Hiraga, A. and Cohen, P. (1986) FEBS Lett. 
194, 85-90. 
MacKintosh, C., Campbell, D.G., Hiraga, A. and Cohen, P. 
(1988) 234, 189-194. 
Hubbard, M.J. and Cohen, P. (1989) Eur. J. Biochem. 180, 
457-465. 
Dent, P., Campbell, D.G., Hubbard, M.J. and Cohen, P. 
(1989) FEBS Lett. 248, 67-72. 
Fiol, C.J., Haseman, J.H., Wang, Y., Roach, P.J., Roeske, 
R.W., Kawalczuk, M. and de Paoli-Roach, A.A. (1988) Arch. 
B&hem. Biophys. 267, 797-802. 
Bradford, M.M. (1976) Anal. Biochem. 72, 248-254. 
Holmes, C.F.B., Campbell, D.G., Caudwell, F.B., Aitken, A. 
and Cohen, P. (1986) Eur. J. Biochem. 155, 173-182. 
Smythe, C., Caudwell, F.B., Ferguson, M. and Cohen, P. 
(1988) EMBO J. 7, 2681-2686. 
Meyer, H.E., Hoffman-Posorske, E., Korte, H. and Heilmeyer, 
L.M.G. (1986) FEBS Lett. 204, 61-66. 
Holmes, C.F.B. (1987) FEBS Lett. 215, 21-24. 
Kemp, B.E. (1980) FEBS Lett. 110, 308-312. 
Hiraga, A. and Cohen, P. (1986) Eur. J. Biochem. 161, 
763-769. 
[16] Hubbard, M.J. and Cohen, P. (1989b) Eur. J. Biochem. in 
press. 
